<div id="readability-page-1" class="page"><h3>Claim 70% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>Innovative Pharmaceutical Biotech ( (HK:0399) ) has issued an update. Starcoin Group Limited has signed a new memorandum of understanding with NASDAQ-listed Newbridge Acquisition Limited and Conflux Foundation to explore a potential de-SPAC transaction involving the group, Conflux and their respective assets or businesses, replacing an earlier MOU with Newbridge alone. The contemplated deal is expected to give Starcoin access to U.S. capital markets for fundraising and to integrate Conflux’s blockchain infrastructure and digital asset technology, which the board believes would strengthen its blockchain initiatives, enhance operational reliability and unlock greater value for shareholders if the transaction proceeds to completion. The most recent analyst rating on (HK:0399) stock is a Sell with a HK$0.18 price target. To see the full list of analyst forecasts on Innovative Pharmaceutical Biotech stock, see the HK:0399 Stock Forecast page. More about Innovative Pharmaceutical Biotech Starcoin Group Limited, formerly Innovative Pharmaceutical Biotech Limited, operates through subsidiaries with a strategic focus on blockchain infrastructure and related digital asset technologies. The group is positioning itself to leverage public-chain ecosystems and smart contract management capabilities to enhance its blockchain-related initiatives and overall value proposition. Average Trading Volume: 39,257,002 Technical Sentiment Signal: Hold Current Market Cap: HK$400.7M Find detailed analytics on 0399 stock on TipRanks’ Stock Analysis page.</div>

00399

GBTC

CORZ

Starcoin Group Limited has signed a memorandum of understanding with Newbridge Acquisition Limited and Conflux Foundation to explore a potential de-SPAC transaction. This deal aims to provide Starcoin access to U.S. capital markets and integrate Conflux’s blockchain technology, enhancing operational reliability and shareholder value. The company, formerly known as Innovative Pharmaceutical Biotech, focuses on blockchain infrastructure and digital asset technologies. The latest analyst rating for its stock (HK:0399) is a Sell with a price target of HK$0.18.

- Innovative Pharmaceutical Biotech has provided an update regarding Starcoin Group Limited's new memorandum of understanding with Newbridge Acquisition Limited and Conflux Foundation, aimed at exploring a potential de-SPAC transaction.  
- This deal intends to facilitate Starcoin's access to U.S. capital markets and enhance its blockchain initiatives, potentially increasing value for shareholders if completed.  
- The current analyst rating for Innovative Pharmaceutical Biotech stock is a Sell, with a price target of HK$0.18.

Tip Ranks

STARCOIN GROUP

Grayscale Bitcoin Trust BTC - ETF

Core Scientific, Inc.

Galaxy Digital

Coinbase

Riot Platforms

Grayscale Litecoin Trust (LTC)

Bitfarms Canada

Newbridge Acquisition - Unit

Hut 8 Mining

Bitdeer Tech

Bakkt

Block

Confluent

Mara

Franklin Exponential Data ETF

VanEck Bitcoin ETF

Global X Cloud Computing ETF

ProShares Bitcoin Strategy ETF

First Trust Indxx Innov

Siren ETF Trust Siren Nasdaq NexGen Economy ETF

WisdomTree Bitcoin Fund

Proshares Big Data Refiners ETF

Franklin Bitcoin ETF

Fidelity Wise Origin Bitcoin Fund - ETF

Bitwise Solana Staking ETF

ARK 21Shares Bitcoin ETF

Global X Data Center & Dgtl Infrs ETF

Grayscale Solana Staking ETF

Bitwise Bitcoin ETF

SPDR S&P Software

ISHRS S&P Glb It

Invesco Galaxy Bitcoin ETF

Keel Infrastructure

Starcoin Expands De-SPAC Talks With Newbridge and Conflux to Bolster Blockchain Push